Technology
Health
Pharmaceutical

Principia Biopharma

$36.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.75 (-2.02%) Today
-$0.75 (-2.02%) Today

Why Robinhood?

You can buy or sell PRNB and other stocks, options, ETFs, and crypto commission-free!

About

Principia Biopharma Inc. Common Stock, also called Principia Biopharma, is a biopharmaceutical company which engages in design and development of small molecule drugs within the fields of autoimmune disease and oncology. Read More It operates through Tailored Covalency platform, which enables to purpose-design and develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. The company was founded by Jack Taunton and Richard A. Miller on October 28, 2008 and is headquartered in South San Francisco, CA.

Employees
Headquarters
South San Francisco, California
Founded
2008
Market Cap
885.24M
Price-Earnings Ratio
Dividend Yield
Average Volume
108.77K
High Today
$37.68
Low Today
$35.50
Open Price
$37.09
Volume
2.18M
52 Week High
$38.05
52 Week Low
$22.00

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
2018 IPO
US
North America

News

Markets InsiderMar 2

Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation

-- Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on low dose corticosteroids -- -- Median Anti-DSG antibodies reduced by up to 65 percent with 12 weeks of treatment -- -- Complete Response rate of 25 percent with 12 weeks of treatment -- -- Results suggest a favorable risk-benefit profile in pemphigus patients; Principia looks to confirm these results in ongoing Phase 3 PEGASUS study -- SOUTH SAN FRANCISCO, Calif., March 02, 2019 (GLOBE NEWSWIRE) -- Prin...

136

Earnings

-$0.39
-$0.26
-$0.13
$0.00
Q3 2018
Q4 2018
Estimated
-$0.31 per share
Actual
Available Mar 19, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.